MedTrace Logo

A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice

NCT02545465 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2017-05-24

No results posted yet for this study

Summary

The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice.

In addition, this study will describe patient demographics and reason for switching

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

Riociguat (Adempas, BAY63-2521)

As per the treating physicians discretion

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-15
Primary Completion
2016-05-31
Completion
2016-08-31

Countries

  • Belgium
  • Canada
  • Colombia
  • Germany
  • Japan
  • Sweden
  • Turkey (Türkiye)

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02545465 on ClinicalTrials.gov